Back to top
more

Corcept Therapeutics (CORT)

(Delayed Data from NSDQ)

$34.79 USD

34.79
394,289

+0.51 (1.49%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $34.77 -0.02 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Apellis (APLS) Dips on Layoffs Amid Syfovre Safety Issues

by Zacks Equity Research

Apellis (APLS) plans to initiate restructuring plans to strengthen its commercial portfolio and curb cash burn.

J&J (JNJ) Seeks Full FDA Nod for Balversa in Urothelial Cancer

by Zacks Equity Research

J&J (JNJ) submits a supplemental new drug application to the FDA for full approval of Balversa to treat urothelial carcinoma.

Invivyd (IVVD) Stock Rises 18% in 3 Months: Here's Why

by Zacks Equity Research

Invivyd's (IVVD) shares rallied almost 18% over the past three months, owing to promising developments in its monoclonal antibody candidate, VYD222, designed to prevent symptomatic COVID-19 infection.

Has Compugen (CGEN) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Compugen (CGEN) and Corcept Therapeutics (CORT) have performed compared to their sector so far this year.

Esperion (ESPR) Aims to Expand Key Drug Labels for Growth

by Zacks Equity Research

Esperion's (ESPR) non-statin approved drugs uptake has continued to be the growth driver since launch. However, the company is currently facing a conflict with its partner, Daiichi Sankyo, regarding milestone payments.

Horizon (HZNP) Up as FTC Pauses Acquisition by Amgen Lawsuit

by Zacks Equity Research

The Federal Trade Commission suspends its ongoing lawsuit to block Horizon's (HZNP) acquisition by Amgen until Sep 18, 2023. The company's stock rises 5.8% in response.

Merck (MRK), Eisai to End Keytruda-Lenvima Combo Cancer Study

by Zacks Equity Research

With the phase III LEAP-010 study failing to show an overall survival benefit for patients with recurrent or metastatic HNSCC, Merck (MRK) and Eisai have decided to close the study.

AstraZeneca's (AZN) Lynparza Gets Expanded Use Nod in Japan

by Zacks Equity Research

AstraZeneca (AZN) gets approval for Lynparza with abiraterone and prednisolone combo in Japan to treat adult patients with BRCA-mutated castration-resistant prostate cancer with distant metastasis.

Novo Nordisk (NVO) Posts Upbeat Data From Heart Failure Study

by Zacks Equity Research

Novo Nordisk (NVO) announces positive results from its label-expanding study of Wegovy to treat patients with heart failure and obesity.

Here's Why You Should Add Corcept (CORT) Stock to Your Portfolio

by Zacks Equity Research

Corcept (CORT), a top-ranked stock, is witnessing incremental sales in its only marketed product, Korlym. It is also making good progress with its promising set of pipeline candidates.

Bionomics (BNOX) Up on Positive Updates on PTSD & SAD Candidate

by Zacks Equity Research

Bionomics (BNOX) gains as it provides updates on further development of its lead pipeline candidate, BNC210, developed for post-traumatic stress disorder and social anxiety disorder.

Agenus (AGEN) to Focus on BOT/BAL Candidate, Stock Falls 7%

by Zacks Equity Research

Agenus (AGEN) to halt all other developmental programs to focus on its BOT/BAL program. The company plans to cut its workforce by 25%.

Fulcrum (FULC) Up as FDA Lifts Clinical Hold on SCD Candidate

by Zacks Equity Research

Fulcrum's (FULC) shares surge as the FDA lifts the clinical hold it had earlier placed on its pipeline candidate FTX-6058, to treat patients with sickle cell disease.

Zoetis' (ZTS) Companion Animal Products to Boost Revenues

by Zacks Equity Research

Zoetis' (ZTS) revenues are expected to boost the pet care and livestock product sales in the quarters ahead. Disease outbreaks and potential supply challenges hurt prospects.

Will Keytruda Remain Merck's (MRK) Key Top-Line Driver?

by Zacks Equity Research

With continued label expansion into new indications, particularly earlier-line launches, Merck's (MRK) Keytruda is expected to remain a key top-line driver.

Apellis (APLS) Updates on Safety Concerns for Syfovre

by Zacks Equity Research

Apellis' (APLS) shares rise as the company provides updates on safety concerns regarding Syfovre, approved for the treatment of geographic atrophy.

Krystal (KRYS) Up 5% on Sale of FDA's Priority Review Voucher

by Zacks Equity Research

Krystal (KRYS) announces the sale of its priority review voucher for a consideration of $100 million. The stock of the company rises 5.2% on the news.

Armata Pharma (ARMP) Stock Surges 130% in a Month: Here's Why

by Zacks Equity Research

Armata Pharma (ARMP) stock skyrockets 130% in a month due to encouraging progress of the company's pathogen-targeting natural and synthetic phage candidates.

Timber (TMBR) to Get Acquired by LEO Pharma for $36M, Stock Up

by Zacks Equity Research

Timber (TMBR) surges as LEO Pharma offers to acquire it for approximately $36 million.

Anebulo (ANEB) Gains on Positive FDA Response for ANEB-001

by Zacks Equity Research

Anebulo (ANEB) gains on positive FDA response for the phase III development of its lead candidate ANEB-001 for treating patients with acute cannabinoid intoxication.

Calliditas (CALT) Up as sNDA for Tarpeyo Gets Priority Review

by Zacks Equity Research

Calliditas (CALT) soars as the supplement new drug application seeking to convert accelerated approval of Tarpeyo delayed-release capsule to full approval gets accepted by the FDA.

Belite Bio (BLTE) Stock Surges 72% in a Month: Here's Why

by Zacks Equity Research

Belite Bio (BLTE) rises 72% in a month due to encouraging progress on the development of the company's lead product candidate Tinlarebant, which is being developed to treat several eye diseases.

Amphastar Pharma (AMPH) Stock Skyrockets 89% YTD: Here's Why

by Zacks Equity Research

Amphastar Pharma (AMPH) shares are up 89.1% year to date due to the acquisition of Baqsimi from Lilly. The company also receives FDA approval for Naloxone.

Here's Why You Should Add Dr. Reddy's (RDY) to Your Portfolio

by Zacks Equity Research

Dr. Reddy's (RDY) continues to enjoy a strong foothold in the global generics market due to its deep generic drugs pipeline. The company is also looking to strengthen its biosimilars portfolio.

Pieris (PIRS) Up On Receiving Milestone Payment From Partner

by Zacks Equity Research

Pieris (PIRS) soars as partner Boston Pharmaceuticals initiated early-stage study of PRS-342/BOS-342, triggering an undisclosed milestone payment to the former.